Sponsor

Ascletis Pharma (China) Co., Limited

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Ascletis Pharma (China) Co., Limited appears in 9 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials9
Recruiting shown3
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

9 shown
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT07743463 · lead sponsor · 2026-08-31
RECRUITING
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT07743450 · lead sponsor · 2026-08-28
RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or OverweightNCT07842640 · lead sponsor · 2026-08-27
RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes MellitusNCT07321678 · lead sponsor · 2026-01-22
COMPLETED
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT07002905 · lead sponsor · 2025-07-03
COMPLETED
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With SemaglutideNCT06972992 · lead sponsor · 2025-04-18
COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With ObesityNCT06679959 · lead sponsor · 2024-09-16
COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With ObesityNCT06680440 · lead sponsor · 2024-08-26
COMPLETED
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Healthy and Obese SubjectsNCT06427590 · lead sponsor · 2024-07-13
COMPLETED

Drugs studied in this sponsor's trials

2 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Ascletis Pharma (China) Co., Limited as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo3
tirzepatide1

Sponsor roles

lead sponsor9
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.